193 related articles for article (PubMed ID: 38365678)
1. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
[TBL] [Abstract][Full Text] [Related]
2. Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy.
Hu ZX; Xu XY; Wang Z; Huang JT; Li WC; Zhang S; Shen J; Zhong BY; Zhu XL
J Hepatocell Carcinoma; 2023; 10():2073-2082. PubMed ID: 38022730
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Hepatol Int; 2022 Oct; 16(5):1150-1160. PubMed ID: 35749019
[TBL] [Abstract][Full Text] [Related]
4. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
[TBL] [Abstract][Full Text] [Related]
5. Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
Guan R; Mei J; Lin W; Deng M; Li S; Guo R
Hepatol Int; 2023 Oct; 17(5):1279-1288. PubMed ID: 37129721
[TBL] [Abstract][Full Text] [Related]
6. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
[TBL] [Abstract][Full Text] [Related]
7. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
Jiang N; Zhong B; Huang J; Li W; Zhang S; Zhu X; Ni C; Shen J
Front Immunol; 2023; 14():1205636. PubMed ID: 37583693
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
[TBL] [Abstract][Full Text] [Related]
10. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.
Shi Q; Zhou X; Zhang Z; Zhang W; Ma J; Yang M; Yu J; Luo J; Liu L; Yan Z
Front Immunol; 2022; 13():1097625. PubMed ID: 36703965
[TBL] [Abstract][Full Text] [Related]
11. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
Front Immunol; 2022; 13():848387. PubMed ID: 35300325
[TBL] [Abstract][Full Text] [Related]
12. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
Acad Radiol; 2024 May; ():. PubMed ID: 38760273
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study.
Gao Y; Lu H; Xiong Z
Front Oncol; 2023; 13():1231359. PubMed ID: 38074659
[TBL] [Abstract][Full Text] [Related]
14. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
15. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
16. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
Sheng Y; Wang Q; Liu H; Wang Q; Chen W; Xing W
Br J Radiol; 2024 Feb; 97(1155):668-679. PubMed ID: 38303541
[TBL] [Abstract][Full Text] [Related]
17. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.
Liu J; Wang P; Shang L; Zhang Z; Tian Y; Chen X; Ma Y; Shao H
Hepatol Int; 2024 Apr; 18(2):595-609. PubMed ID: 37843788
[TBL] [Abstract][Full Text] [Related]
18. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Xia WL; Zhao XH; Guo Y; Hu HT; Cao GS; Li Z; Fan WJ; Xu SJ; Li HL
Clin Transl Gastroenterol; 2023 May; 14(5):e00581. PubMed ID: 36920551
[TBL] [Abstract][Full Text] [Related]
20. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
